Matt Miksic
Stock Analyst at Barclays
(3.89)
# 660
Out of 5,042 analysts
297
Total ratings
61.04%
Success rate
5.97%
Average return
Main Sectors:
Stocks Rated by Matt Miksic
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DXCM DexCom | Maintains: Equal-Weight | $98 → $80 | $60.14 | +33.02% | 8 | Nov 3, 2025 | |
| ATEC Alphatec Holdings | Maintains: Overweight | $22 → $23 | $18.09 | +27.14% | 4 | Nov 3, 2025 | |
| EW Edwards Lifesciences | Maintains: Overweight | $95 → $99 | $82.42 | +20.12% | 30 | Oct 31, 2025 | |
| BLCO Bausch + Lomb | Maintains: Equal-Weight | $16 → $17 | $14.89 | +14.17% | 6 | Oct 31, 2025 | |
| SYK Stryker | Maintains: Overweight | $443 → $453 | $355.57 | +27.40% | 24 | Oct 22, 2025 | |
| ABT Abbott Laboratories | Maintains: Overweight | $159 → $162 | $123.23 | +31.46% | 30 | Oct 17, 2025 | |
| GEHC GE HealthCare Technologies | Initiates: Equal-Weight | $86 | $75.22 | +14.33% | 1 | Oct 13, 2025 | |
| COO The Cooper Companies | Initiates: Overweight | $85 | $68.95 | +23.28% | 1 | Oct 13, 2025 | |
| ALC Alcon | Initiates: Equal-Weight | $86 | $72.96 | +17.87% | 10 | Oct 13, 2025 | |
| BSX Boston Scientific | Maintains: Overweight | $133 → $136 | $99.66 | +36.46% | 19 | Oct 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $7.09 | +323.13% | 1 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $3.5 | $1.65 | +112.12% | 1 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $55 → $58 | $52.51 | +10.46% | 8 | Aug 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $266 → $300 | $316.82 | -5.31% | 9 | Aug 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $51 | $14.07 | +262.60% | 7 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $41 → $36 | $18.31 | +96.61% | 22 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $21 | $14.57 | +44.18% | 14 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $165 → $176 | $188.18 | -6.47% | 13 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $261 → $241 | $177.50 | +35.78% | 1 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $12 | $3.91 | +206.91% | 2 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $684 → $635 | $534.16 | +18.88% | 7 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $103 | $59.92 | +71.90% | 15 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $118 → $112 | $99.33 | +12.76% | 7 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $4.56 | +382.36% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $109 | $89.84 | +21.33% | 21 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $100 | $63.28 | +58.03% | 8 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $722 → $418 | $137.05 | +205.01% | 3 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $28 | $16.74 | +67.26% | 2 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $67 | $12.44 | +438.59% | 1 | Mar 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $480 | $5.32 | +8,922.56% | 1 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $87 | $12.15 | +616.05% | 14 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $4.24 | +489.62% | 5 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $9 | $7.53 | +19.52% | 1 | Dec 12, 2016 |
DexCom
Nov 3, 2025
Maintains: Equal-Weight
Price Target: $98 → $80
Current: $60.14
Upside: +33.02%
Alphatec Holdings
Nov 3, 2025
Maintains: Overweight
Price Target: $22 → $23
Current: $18.09
Upside: +27.14%
Edwards Lifesciences
Oct 31, 2025
Maintains: Overweight
Price Target: $95 → $99
Current: $82.42
Upside: +20.12%
Bausch + Lomb
Oct 31, 2025
Maintains: Equal-Weight
Price Target: $16 → $17
Current: $14.89
Upside: +14.17%
Stryker
Oct 22, 2025
Maintains: Overweight
Price Target: $443 → $453
Current: $355.57
Upside: +27.40%
Abbott Laboratories
Oct 17, 2025
Maintains: Overweight
Price Target: $159 → $162
Current: $123.23
Upside: +31.46%
GE HealthCare Technologies
Oct 13, 2025
Initiates: Equal-Weight
Price Target: $86
Current: $75.22
Upside: +14.33%
The Cooper Companies
Oct 13, 2025
Initiates: Overweight
Price Target: $85
Current: $68.95
Upside: +23.28%
Alcon
Oct 13, 2025
Initiates: Equal-Weight
Price Target: $86
Current: $72.96
Upside: +17.87%
Boston Scientific
Oct 2, 2025
Maintains: Overweight
Price Target: $133 → $136
Current: $99.66
Upside: +36.46%
Aug 27, 2025
Initiates: Overweight
Price Target: $30
Current: $7.09
Upside: +323.13%
Aug 27, 2025
Initiates: Overweight
Price Target: $3.5
Current: $1.65
Upside: +112.12%
Aug 21, 2025
Maintains: Equal-Weight
Price Target: $55 → $58
Current: $52.51
Upside: +10.46%
Aug 21, 2025
Maintains: Equal-Weight
Price Target: $266 → $300
Current: $316.82
Upside: -5.31%
Aug 8, 2025
Maintains: Overweight
Price Target: $53 → $51
Current: $14.07
Upside: +262.60%
Aug 4, 2025
Maintains: Overweight
Price Target: $41 → $36
Current: $18.31
Upside: +96.61%
Jul 30, 2025
Maintains: Overweight
Price Target: $24 → $21
Current: $14.57
Upside: +44.18%
Jul 17, 2025
Maintains: Equal-Weight
Price Target: $165 → $176
Current: $188.18
Upside: -6.47%
Jun 3, 2025
Maintains: Overweight
Price Target: $261 → $241
Current: $177.50
Upside: +35.78%
May 5, 2025
Maintains: Overweight
Price Target: $16 → $12
Current: $3.91
Upside: +206.91%
Apr 24, 2025
Maintains: Overweight
Price Target: $684 → $635
Current: $534.16
Upside: +18.88%
Feb 24, 2025
Maintains: Overweight
Price Target: $100 → $103
Current: $59.92
Upside: +71.90%
Feb 10, 2025
Maintains: Underweight
Price Target: $118 → $112
Current: $99.33
Upside: +12.76%
Jan 7, 2025
Initiates: Overweight
Price Target: $22
Current: $4.56
Upside: +382.36%
Nov 26, 2024
Maintains: Overweight
Price Target: $105 → $109
Current: $89.84
Upside: +21.33%
May 13, 2022
Assumes: Outperform
Price Target: $100
Current: $63.28
Upside: +58.03%
May 4, 2022
Maintains: Outperform
Price Target: $722 → $418
Current: $137.05
Upside: +205.01%
Mar 2, 2022
Maintains: Outperform
Price Target: $31 → $28
Current: $16.74
Upside: +67.26%
Mar 1, 2022
Maintains: Outperform
Price Target: $68 → $67
Current: $12.44
Upside: +438.59%
Jan 7, 2022
Initiates: Outperform
Price Target: $480
Current: $5.32
Upside: +8,922.56%
Nov 3, 2021
Maintains: Outperform
Price Target: $84 → $87
Current: $12.15
Upside: +616.05%
Aug 10, 2021
Maintains: Outperform
Price Target: $24 → $25
Current: $4.24
Upside: +489.62%
Dec 12, 2016
Initiates: Sell
Price Target: $9
Current: $7.53
Upside: +19.52%